FUJIFILM Diosynth Biotechnologies Denmark ApS – FDA 483, Nov 12, 2024
An FDA inspection of Fujifilm Diosynth Biotechnologies Denmark ApS in Hillerod revealed significant deficiencies across its drug substance manufacturing operations. The firm's Quality Unit demonstrated inadequate oversight, failing to ensure effective quality management, proper investigations, and adherence to procedures. Additionally, issues with electronic record integrity and incomplete production documentation were observed, indicating a broad lack of control over critical manufacturing processes.
- Inspection date
- November 12, 2024
- Product type
- drugs
ID · 2ec35f9a-5f16-4fee-ad57-6599d261113d
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.